

September 21, 1965

Dr. Gerald L. Klerman  
Yale Department of Psychiatry  
Yale Psychiatric Institute  
Yale University School of Medicine  
New Haven, Connecticut

Dear Gerry:

First, let me thank you for your kindness in taking me home some weeks ago. The next few days are a blur but by now my mother and my family are adjusting to the loss, as well as one can.

I have just read your report on the clinical pharmacology of imipramine. There are many aspects of the pharmacology of imipramine which are new to me, and I found myself reading it a number of times during the past week. If there is any question, it is only to the emphasis on monoamines and the limited information regarding the cholinergic aspects of this compound. I cannot help but feel that the antidepressant features of this compound may be more related to its central effects on cholinergic mechanisms than on any other aspect of brain function that has been described so far. We lack the methods to study this system with sufficient quantitative accuracy so that this aspect will have to await further study.

I would be very grateful if you would make available to me a reprint of this report when it is available.

My best regards.

Sincerely yours,

Max Fink, M.D.  
Professor of Psychiatry

MF:kp